Success Metrics

Completion Rate
0%(0/1)
Active Trials
2(67%)
Terminated
1(33%)

Phase Distribution

Ph not_applicable
2
67%
Ph phase_3
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Terminated(1)

Detailed Status

Active, not recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 31 (33.3%)
N/A2 (66.7%)

Trials by Status

active_not_recruiting267%
terminated133%

Recent Activity

2 active trials
Showing 3 of 3
active_not_recruitingnot_applicable

Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

NCT04763200
active_not_recruitingnot_applicable

SAVE-PCI: NyokAssist™ Small-Bore VAD vs. IABP in Elective High-Risk PCI

NCT07010965
terminatedphase_3

Protect II, A Prospective, Multicenter Randomized Controlled Trial

NCT00562016

Clinical Trials (3)

Showing 3 of 3 trials
NCT04763200Not Applicable

Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

Active Not Recruiting
NCT07010965Not Applicable

SAVE-PCI: NyokAssist™ Small-Bore VAD vs. IABP in Elective High-Risk PCI

Active Not Recruiting
NCT00562016Phase 3

Protect II, A Prospective, Multicenter Randomized Controlled Trial

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
3